foxo4-dri human trial senolytic Development of a novel by precise disruption of FOXO4-p53 complex FOXO4-DRI - Averix Labs

Common (5-15% of users): Mild injection site reactions, minor digestive changes Uncommon (1-5%): Sleep changes, temporary fatigue, mild headache Rare (under 1%): Dizziness, flushing, mood changes Very Rare: Serious adverse effects rarely reported in community use Theoretical Concerns BPC-157s ability to stimulate angiogenesis (blood vessel formation) raises theoretical questions about its use in individuals with active cancer or high cancer risk

These are the same mechanisms that traditional immunotherapy uses, but peptide immunotherapy appears to achieve them faster and with fewer risks

2001

4) Cost transparency & patient trust Pricing for compounded medications is notoriously opaque and varies widely by pharmacy